All Title Author
Keywords Abstract

Risk Stratification Treatment of Pediatric Rhabdomyosarcoma: South Egypt Cancer Institute Experience

DOI: 10.4236/jct.2012.35076, PP. 595-601

Keywords: Pediatric, Rhabdomyosarcoma and Risk

Full-Text   Cite this paper   Add to My Lib


Risk stratification allows tailoring of treatment protocol using, for selected patients, reduced total chemotherapy exposure, including decreases in alkylator therapy and avoidance of agents with recognized risk of late complications (anthracyclines), elimination of irradiation and reduction of radiotherapy dose. Patients and Methods: Twenty-nine newly diagnosed pediatric rhabdomyosarcoma patients attended the pediatric oncology department between January 2008 and May 2011. Patients were divided into 3 groups according to age, stage, group, pathology and site of the tumor. Treatment protocol tailored according to risk group. Results: Twenty-nine newly diagnosed pediatric rhabdomyosarcoma patients were evaluated. Seven patients had low risk, Intermediate risk included 12 patients, and 10 patients had high risk. After three years median follow up, event free survival was 51.7% for all patients however it was 86%, 67% and 10% for low, intermediate and high risk respectively (P = 0.0002). There was statistical difference for survival among different sites, histology, clinical group and stage as risk factors within each risk group, no statistically survival significance of any of these factors within the same risk group. Conclusion: Risk stratification is the best single predictor factor for pediatric rhabdomyosarcoma and allows tailoring of the treatment protocol. For selected patients, reductions in total chemotherapy exposure, elimination of irradiation in selected low risk patients and reduction of radiotherapy dose according to postoperative margin and nodal status is safe.


[1]  R. B. Raney Jr., M. Tefft, D. M. Hays and T. J. Triche, “Rhabdomyosarcoma and the Undifferentiated Sarcomas,” In: P. A. Pizzo and D. G. Poplack, Eds., Principles and Practice of Pediatric Oncology, Lippincott, Philadelphia, 1993, pp. 769-794.
[2]  R. Dagher and L. Helman, “Rhabdomyosarcoma: An Overview,” Oncologist, Vol. 4, No. 1, 1999, pp. 34-44.
[3]  I. Q. Iyad Sultan, S.Yaser, C.Rodriguez-Galindo, and A.Ferrari, “Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients,” Oncology & Radiotherapy, Vol. 27, No. 20, 2009, pp. 3391-3397. doi:10.1002/cncr.24424
[4]  W. M. Crist, et al., “Intergroup Rhabdomyosarcoma Study-IV: Results for Patients with Nonmetastatic Disease,” Journal of Clinical Oncology, Vol. 19, No. 12, 2001, pp. 3091-3102.
[5]  X. J. Yuan, et al., “Treatment Outcome of Rhabdomyosarcoma in Hong Kong Chinese Children,” Hong Kong Medical Journal, Vol. 14, No. 2, 2008, pp. 116-123.
[6]  A. S. Pappo, et al., “Biology and Therapy of Pediatric Rhabdomyosarcoma,” Journal of Clinical Oncology, Vol. 13, No. 8, 1995, pp. 2123-2139. doi:10.1007/BF02368677
[7]  J. L. Meza, et al., “Analysis of Prognostic Factors in Patients with Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children’s Oncology Group,” Journal of Clinical Oncology, Vol. 24, No. 24, 2006, pp. 3844-3851. doi:10.1200/JCO.2005.05.3801
[8]  D. O. Walterhouse, et al., “Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children with Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children’s Oncology Group Study,” Journal of Clinical Oncology, Vol. 22, No. 8, 2004, pp. 1398-1403. doi:10.1200/JCO.2004.05.184
[9]  F. B. Ruymann and A. C. Grovas, “Progress in the DiagNosis and Treatment of Rhabdomyosarcoma and Related Soft Tissue Sarcomas,” Cancer Investigation, Vol. 18, No. 3, 2000, pp. 223-241. doi:10.3109/07357900009031827
[10]  C. Akyuz, et al., “Turkish Experience with Rhabdomyosarcoma: An Analysis of 255 Patients for 20 Years,” The Turkish Journal of Pediatrics, Vol. 40, No. 4, 1998, pp. 491-501. doi:10.1016/S0959-8049(98)00024-0
[11]  F. Flamant, et al., “Treatment of Non-Metastatic Rhabdomyosarcomas in Childhood and Adolescence. Results of the Second Study of the International Society of Paediatric Oncology: MMT84,” European Journal of Cancer, Vol. 34, No. 7, 1998, pp. 1050-1062.
[12]  A. S. Pappo, et al., “Survival after Relapse in Children and Adolescents with Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Study Group,” Journal of Clinical Oncology, Vol. 17, No. 11, 1999, pp. 3487-3493.
[13]  E. Koscielniak, et al., “Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86,” Journal of Clinical Oncology, Vol. 17, No. 12, 1999, pp. 3706-3719.
[14]  C. A. Arndt, et al., “Vincristine, Actinomycin, and Cyclophosphamide Compared with Vincristine, Actinomycin, and Cyclophosphamide Alternating with Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children’s Oncology Group Study D9803,” Journal of Clinical Oncology, Vol. 27, No. 31, 2009, pp. 5182-5188. doi:10.1200/JCO.2009.22.3768
[15]  A. S. Pappo, et al., “Two Consecutive Phase II Window Trials of Irinotecan alone or in Combination with Vincristine for the treatment of Metastatic Rhabdomyosarcoma: The Children’s Oncology Group,” Journal of Clinical Oncology, Vol. 25, No. 4, 2007, pp. 362-369. doi:10.1200/JCO.2006.07.1720
[16]  S. L. Wolden, et al., “Indications for Radiotherapy and Chemotherapy after Complete Resection in Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Studies I to III,” Journal of Clinical Oncology, Vol. 17, No. 11, 1999, pp. 3468-3475.
[17]  L. M. Smith, et al., “Which Patients with Microscopic Disease and Rhabdomyosarcoma Experience Relapse after Therapy? A Report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group,” Journal of Clinical Oncology, Vol. 19, No. 20, 2001, pp. 4058-4064.
[18]  S. S. Donaldson, et al., “Results from the IRS-IV Randomized Trial of Hyperfractionated Radiotherapy in Children with Rhabdomyosarcoma—A Report from the IRSG,” International Journal of Radiation Oncology, Biology, Physics, Vol. 51, No. 3, 2001, pp. 718-728.doi:10.1016/S0360-3016(01)01709-6
[19]  C, M. T. Hua and S. L. Spunt, “Early Results of a Prospective Study Delivering Limited Margin Radiotherapy for Pediatric Patients with Rhabdomyosarcoma,” International Journal of Radiation Oncology, Biology, Physics, Vol. 69, Suppl. 3, 2007, p. S37.doi:10.1016/j.ijrobp.2007.07.068
[20]  M. D. Wharam, J. M. James Anderson, J. C. Breneman, S. S. Donaldson, T. J. Fitzgerald, J. Michalski, L. A. Teot, E. S. Wiener and W. H. Meyer, “Failure Pattern and Factors Predictive of Local Failure in Rhabdomyosarcoma: A Report of Group III Patients on the Third Intergroup Rhabdomyosarcoma Study,” Journal of Clinical Oncology, Vol. 22, No. 10, 2004, pp. 1902-1908.
[21]  B. Weigel, E. Lyden J. R. Anderson, A. Galster, C. A. Arndt, J. Michalski, D. S. Hawkins and W. H. Meyer, “Early Results from Children’s Oncology Group (COG) ARST0431: Intensive Multidrug Therapy for Patients with Metastatic Rhabdomyosarcoma (RMS),” Journal of Clinical Oncology, Vol. 28, Suppl. 15, 2010, p. 9503.


comments powered by Disqus